Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 74,081 | 129,126 | 132,139 | 179,894 | 195,822 |
| Marketable Securities | 57,501 | 122,744 | 144,101 | 131,106 | 145,219 |
| Receivables | 265,384 | 231,516 | 190,121 | 129,185 | 115,727 |
| Inventories | 146,953 | 155,202 | 157,759 | 110,458 | 84,669 |
| Other current assets | 55,846 | 25,374 | 20,390 | 15,716 | 32,632 |
| TOTAL | $599,765 | $663,962 | $644,510 | $566,359 | $574,069 |
| Non-Current Assets | |||||
| Investments And Advances | 48,757 | 28,590 | 1,907 | 808 | 1,125 |
| Other Non-Current Assets | 376,502 | 10,061 | 10,271 | 10,523 | 10,820 |
| TOTAL | $425,259 | $38,651 | $12,178 | $11,331 | $11,945 |
| Total Assets | $1,025,024 | $702,613 | $656,689 | $577,690 | $586,014 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 112,336 | 134,021 | 133,932 | 58,296 | 101,407 |
| Accrued Expenses | 15,014 | 10,610 | 5,135 | 15,185 | 10,085 |
| Other current liabilities | 1,993 | 2,256 | 2,947 | 4,627 | 3,298 |
| TOTAL | $156,810 | $171,889 | $160,209 | $90,679 | $125,114 |
| Non-Current Liabilities | |||||
| Long Term Debt | 245,340 | 245,037 | 244,733 | 244,429 | 244,158 |
| Deferred Revenues | 26,399 | 23,911 | 17,079 | 11,414 | 9,093 |
| Other Non-Current Liabilities | 7,308 | 7,588 | 7,860 | 8,133 | 8,419 |
| TOTAL | $260,996 | $254,292 | $259,191 | $264,647 | $268,743 |
| Total Liabilities | $417,806 | $426,181 | $419,400 | $355,326 | $393,857 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 158,760 | 158,666 | 158,755 | 157,071 | 155,665 |
| Common Shares | 159 | 159 | 159 | 156 | 156 |
| Retained earnings | -1,105,052 | -1,495,947 | -1,524,134 | -1,529,194 | -1,552,525 |
| Other shareholders' equity | -234 | 8 | -117 | 6 | -383 |
| TOTAL | $607,218 | $276,432 | $237,289 | $222,364 | $192,157 |
| Total Liabilities And Equity | $1,025,024 | $702,613 | $656,689 | $577,690 | $586,014 |